Mary Jeanne Kreek

List of Publications by Year
in descending order

179	9,874	44069	39675
papers	citations	48 h-index	94 g-index

182	182	182	7783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single-nucleotide polymorphism in the human mu opioid receptor gene alters Î²-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9608-9613.	7.1	1,075
2	Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience, 2005, 8, 1450-1457.	14.8	925
3	1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet, The, 2003, 361, 662-668.	13.7	416
4	Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments. Pharmacological Reviews, 2005, 57, 1-26.	16.0	338
5	Pharmacotherapy of addictions. Nature Reviews Drug Discovery, 2002, 1, 710-726.	46.4	326
6	Treatment of opioid-induced constipation with oral naloxone: A pilot study. Clinical Pharmacology and Therapeutics, 1992, 52, 90-95.	4.7	240
7	Methadoneâ€Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. Annals of the New York Academy of Sciences, 2000, 909, 186-216.	3.8	215
8	HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA - Journal of the American Medical Association, 1989, 261, 1008-1012.	7.4	209
9	Increased Attributable Risk Related to a Functional Î¼-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden. Neuropsychopharmacology, 2005, 30, 417-422.	5.4	198
10	Genetic susceptibility to heroin addiction: a candidate gene association study. Genes, Brain and Behavior, 2008, 7, 720-729.	2.2	189
11	Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. Journal of Clinical Investigation, 2012, 122, 3387-3393.	8.2	178
12	Î¹-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences, 2012, 35, 587-596.	8.6	165
13	Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Molecular Psychiatry, 2004, 9, 547-549.	7.9	155
14	ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Human Molecular Genetics, 2008, 17, 2219-2227.	2.9	150
15	Nalmefene Induced Elevation in Serum Prolactin in Normal Human Volunteers: Partial Kappa Opioid Agonist Activity?. Neuropsychopharmacology, 2005, 30, 2254-2262.	5.4	121
16	One-Year and Cumulative Retention as Predictors of Success in Methadone Maintenance Treatment: A Comparison of Two Clinics in the United States and Israel. Journal of Addictive Diseases, 2008, 27, 11-25.	1.3	116
17	History and current status of opioid maintenance treatments: blending conference session. Journal of Substance Abuse Treatment, 2002, 23, 93-105.	2.8	110
18	Genes Associated With Addiction: Alcoholism, Opiate, and Cocaine Addiction. NeuroMolecular Medicine, 2004, 5, 085-108.	3.4	109

#	Article	IF	Citations
19	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behavior Genetics, 2016, 46, 151-169.	2.1	98
20	Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. Neuropharmacology, 2004, 47, 324-344.	4.1	97
21	Neuropathic and chronic pain stimuli downregulate central Î¼ -opioid and dopaminergic transmission. Trends in Pharmacological Sciences, 2010, 31, 299-305.	8.7	96
22	ACTH, cortisol and Î²-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides, 1984, 5, 277-278.	2.2	94
23	Nalmefene Causes Greater Hypothalamic-Pituitary-Adrenal Axis Activation than Naloxone in Normal Volunteers: Implications for the Treatment of Alcoholism. Alcoholism: Clinical and Experimental Research, 1998, 22, 1430-1436.	2.4	93
24	Narcotic blockade. Archives of Internal Medicine, 1966, 118, 304-9.	3.8	92
25	Methadone disposition in patients with chronic liver disease. Clinical Pharmacology and Therapeutics, 1981, 30, 353-362.	4.7	91
26	Cocaine, Dopamine and the Endogenous Opioid System. Journal of Addictive Diseases, 1996, 15, 73-96.	1.3	91
27	Pharmacotherapy in the Treatment of Addiction: Methadone. Journal of Addictive Diseases, 2010, 29, 200-216.	1.3	91
28	Opiates, opioids and addiction. Molecular Psychiatry, 1996, 1, 232-54.	7.9	91
29	CYP2B6SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addiction Biology, 2013, 18, 709-716.	2.6	88
30	Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 1070-6.	2.5	86
31	Circadian rhythms and levels of Î²-endorphin, acth, and cortisol during chronic methadone maintenance treatment in humans. Life Sciences, 1983, 33, 409-411.	4.3	83
32	Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochemical Research, 1996, 21, 1469-1488.	3.3	82
33	Ethnic diversity of DNA methylation in the OPRM1 promoter region in lymphocytes of heroin addicts. Human Genetics, 2010, 127, 639-649.	3.8	76
34	Altered HPA Axis Responsivity to Metyrapone Testing in Methadone Maintained Former Heroin Addicts with Ongoing Cocaine Addiction. Neuropsychopharmacology, 2001, 24, 568-575.	5.4	74
35	Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. Journal of Pharmacology and Experimental Therapeutics, 1999, 288, 260-9.	2.5	67
36	Opiate and cocaine addiction: from bench to clinic and back to the bench. Current Opinion in Pharmacology, 2009, 9, 74-80.	3.5	65

#	Article	IF	Citations
37	Stress-related genes and heroin addiction: A role for a functional FKBP5 haplotype. Psychoneuroendocrinology, 2014, 45, 67-76.	2.7	62
38	Cocaine Abuse Sharply Reduced in an Effective Methadone Maintenance Program. Journal of Addictive Diseases, 1999, 18, 63-75.	1.3	61
39	Stereoselective disposition of methadone in man. Life Sciences, 1979, 24, 925-932.	4.3	60
40	Current status of opioid addiction treatment and related preclinical research. Science Advances, 2019, 5, eaax9140.	10.3	60
41	Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study. Alcoholism: Clinical and Experimental Research, 1997, 21, 906-909.	2.4	58
42	Genome-wide association study identifies genes that may contribute to risk for developing heroin addiction. Psychiatric Genetics, 2010, 20, 207-214.	1.1	58
43	Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: Potential in studies of addiction. American Journal of Medical Genetics Part A, 2000, 96, 604-615.	2.4	56
44	Novel and previously reported singleâ€nucleotide polymorphisms in the human 5â€HT_{1B} receptor gene: No association with cocaine or alcohol abuse or dependence. American Journal of Medical Genetics Part A, 2001, 105, 489-497.	2.4	54
45	Alterations of expression of inflammation/immune-related genes in the dorsal and ventral striatum of adult C57BL/6J mice following chronic oxycodone self-administration: a RNA sequencing study. Psychopharmacology, 2017, 234, 2259-2275.	3.1	54
46	Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL/6ÂJ mice. Psychopharmacology, 2014, 231, 1277-1287.	3.1	53
47	Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Molecular Brain Research, 1999, 66, 184-187.	2.3	51
48	Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Research, 2010, 1314, 235-252.	2.2	51
49	Sex differences in responsiveness to the prescription opioid oxycodone in mice. Pharmacology Biochemistry and Behavior, 2016, 148, 99-105.	2.9	50
50	Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence. Neuropsychopharmacology, 2018, 43, 739-750.	5.4	50
51	Sustained Withdrawal Allows Normalization of In Vivo [11C]N-Methylspiperone Dopamine D2 Receptor Binding after Chronic Binge Cocaine A Positron Emission Tomography Study in Rats. Neuropsychopharmacology, 1998, 19, 146-153.	5.4	49
52	Mouse Model of the OPRM1 (A118G) Polymorphism: Differential Heroin Self-Administration Behavior Compared with Wild-Type Mice. Neuropsychopharmacology, 2015, 40, 1091-1100.	5.4	49
53	Effect of Severe Alcoholic Liver Disease on the Disposition of Methadone in Maintenance Patients. Alcoholism: Clinical and Experimental Research, 1985, 9, 349-354.	2.4	48
54	Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology, 2015, 6, 190.	3.5	47

#	Article	IF	Citations
55	Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction, 2000, 95, 1647-1653.	3.3	46
56	Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addiction Biology, 2007, 12, 496-502.	2.6	45
57	Stress Responsivity, Addiction, and a Functional Variant of the Human Mu-Opioid Receptor Gene. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 74-78.	3.4	45
58	Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics Journal, 2010, 10, 232-242.	2.0	44
59	Quantitation of Methadone Eenantiomers in Humans Using Stable Isotope-labeled [2H3]-, [2H5]-, and [2H8]methadone. Journal of Pharmaceutical Sciences, 1982, 71, 40-43.	3.3	43
60	Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats. Psychopharmacology, 2012, 220, 163-172.	3.1	43
61	Blockade of alcohol escalation and â€œrelapseâ€•drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice. Psychopharmacology, 2017, 234, 2955-2970.	3.1	43
62	â€œEffects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in ratsâ€• Psychopharmacology, 2017, 234, 2219-2231.	3.1	41
63	Reduced Hypothalamic POMC and Anterior Pituitary CRF1 Receptor mRNA Levels After Acute, but Not Chronic, Daily "Binge"Intragastric Alcohol Administration. Alcoholism: Clinical and Experimental Research, 2000, 24, 1575-1582.	2.4	40
64	Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Annals of the New York Academy of Sciences, 2011, 1231, 65-72.	3.8	39
65	Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice. Neuroscience, 2015, 285, 34-46.	2.3	39
66	Chronic Oxycodone Self-administration Altered Reward-related Genes in the Ventral and Dorsal Striatum of C57BL/6J Mice: An RNA-seq Analysis. Neuroscience, 2018, 393, 333-349.	2.3	39
67	Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. New York State Journal of Medicine, 1973, 73, 2773-7.	0.1	38
68	Involvement of Endocannabinoids in Alcohol â€œBingeâ€•Drinking: Studies of Mice with Human Fatty Acid Amide Hydrolase Genetic Variation and After CB1 Receptor Antagonists. Alcoholism: Clinical and Experimental Research, 2016, 40, 467-473.	2.4	36
69	Quantitation of dopamine transporter mrna in the rat brain: Mapping, effects of ?binge? cocaine administration and withdrawal. , 1997, 26, 55-61.		34
70	Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology, 1998, 137, 326-332.	3.1	34
71	Variable Dose Naltrexone-Induced Hypothalamic-Pituitary-Adrenal Stimulation in Abstinent Alcoholics: A Preliminary Study. Alcoholism: Clinical and Experimental Research, 1999, 23, 502-508.	2.4	34
72	Muâ€•opioid receptor A118G polymorphism in healthy volunteers affects hypothalamicâ€“pituitaryâ€“adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addiction Biology, 2013, 18, 325-331.	2.6	34

#	Article	IF	Citations
73	Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice. International Journal of Neuropsychopharmacology, 2018, 21, 847-857.	2.1	32
74	Sex differences after chronic stress in the expression of opioid-, stress- and neuroplasticity-related genes in the rat hippocampus. Neurobiology of Stress, 2018, 8, 33-41.	4.0	32
75	Selective regulation of dopamine transporter binding in the shell of the nucleus accumbens by adrenalectomy and corticosterone-replacement. , 1998, 30, 334-337.		31
76	Catecholâ€Oâ€methyltransferase (COMT) gene variants: Possible association of the Val158Met variant with opiate addiction in hispanic women. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 793-798.	1.7	31
77	Haplotype block structure of the genomic region of the mu opioid receptor gene. Journal of Human Genetics, 2011, 56, 147-155.	2.3	31
78	Alcohol: A stimulant activating brain stress responsive systems with persistent neuroadaptation. Neuropharmacology, 2014, 87, 51-58.	4.1	31
79	Quantitative Analysis of Methadone in Biological Fluids Using Deuterium-Labeled Methadone and GLC-Chemical-Ionization Mass Spectrometry. Journal of Pharmaceutical Sciences, 1977, 66, 1579-1582.	3.3	30
80	Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: Vulnerability to relapse to heroin-seeking in rats. Physiology and Behavior, 2015, 139, 127-135.	2.1	30
81	Effects of Ethanol on Human Natural Killer Cell Activity: In Vitro and Acute, Low-Dose In Vivo Studies. Alcoholism: Clinical and Experimental Research, 1994, 18, 1361-1367.	2.4	29
82	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. Drug and Alcohol Dependence, 2014, 145, 101-105.	3.2	29
83	Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration. Neuropharmacology, 2016, 105, 639-650.	4.1	29
84	Effects of handling and vehicle injections on adrenocorticotropic and corticosterone concentrations in Sprague-Dawley compared with Lewis rats. Journal of the American Association for Laboratory Animal Science, 2015, 54, 35-9.	1.2	29
85	Cellâ€specific effects of variants of the 68â€base pair tandem repeat on prodynorphin gene promoter activity. Addiction Biology, 2011, 16, 334-346.	2.6	27
86	Adolescent oxycodone self administration alters subsequent oxycodone-induced conditioned place preference and anti-nociceptive effect in C57BL/6J mice in adulthood. Neuropharmacology, 2016, 111, 314-322.	4.1	27
87	Impact of Pharmacological Manipulation of the Î¹-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 1-8.	2.5	27
88	Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. Journal of Pharmacology and Experimental Therapeutics, 1996, 276, 1128-35.	2.5	27
89	Bidirectional translational research: Progress in understanding addictive diseases. Neuropharmacology, 2009, 56, 32-43.	4.1	26
90	Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression. Neuroscience, 2014, 258, 280-291.	2.3	26

#	Article	IF	Citations
91	Replication of an Effective Opiate Addiction Pharmacotherapeutic Treatment Model. Journal of Maintenance in the Addictions, 2000, 1, 5-13.	0.1	26
92	Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference. Neuroscience, 2018, 393, 236-257.	2.3	24
93	Role of a Functional Human Gene Polymorphism in Stress Responsivity and Addictions. Clinical Pharmacology and Therapeutics, 2008, 83, 615-618.	4.7	23
94	Nerve growth factor Î² polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics Journal, 2012, 12, 319-327.	2.0	23
95	Synaptic Plasticity and Signal Transduction Gene Polymorphisms and Vulnerability to Drug Addictions in Populations of European or African Ancestry. CNS Neuroscience and Therapeutics, 2015, 21, 898-904.	3.9	21
96	Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. Brain Research, 2017, 1662, 75-86.	2.2	20
97	Hypothalamicâ€specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice. Genes, Brain and Behavior, 2017, 16, 449-461.	2.2	20
98	Sex Differences in Neuroplasticity- and Stress-Related Gene Expression and Protein Levels in the Rat Hippocampus Following Oxycodone Conditioned Place Preference. Neuroscience, 2019, 410, 274-292.	2.3	20
99	Evidence for association of two variants of the nociceptin/orphanin FQ receptor gene OPRL1 with vulnerability to develop opiate addiction in Caucasians. Psychiatric Genetics, 2010, 20, 65-72.	1.1	19
100	Addictions and Stress: Clues for Cocaine Pharmacotherapies. Current Pharmaceutical Design, 2013, 19, 7065-7080.	1.9	19
101	Involvement of Activated Brain Stress Responsive Systems in Excessive and â€œRelapseâ€•Alcohol Drinking in Rodent Models: Implications for Therapeutics. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 9-20.	2.5	18
102	Combination of Clinically Utilized Kappaâ€Opioid Receptor Agonist Nalfurafine With Lowâ€Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice. Alcoholism: Clinical and Experimental Research, 2019, 43, 1077-1090.	2.4	18
103	Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [S] guanosine 5â€²-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. Neuroscience, 2010, 169, 751-757.	2.3	17
104	Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 118-123.	4.8	17
105	The Î¼-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. Pharmacogenomics, 2017, 18, 1387-1391.	1.3	17
106	V1b Receptor Antagonist <scp>SSR</scp>149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice. Alcoholism: Clinical and Experimental Research, 2018, 42, 195-205.	2.4	17
107	Specificity of Antibody Tests for Human Immunodeficiency Virus in Alcohol and Parenteral Drug Abusers with Chronic Liver Disease. Alcoholism: Clinical and Experimental Research, 1988, 12, 687-690.	2.4	15
108	Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry. Pharmacogenomics, 2015, 16, 1329-1342.	1.3	15

#	Article	IF	Citations
109	Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. Pharmacogenomics, 2018, 19, 95-104.	1.3	15
110	Re-evaluation of the KMSK scales, rapid dimensional measures of self-exposure to specific drugs: Gender-specific features. Drug and Alcohol Dependence, 2018, 190, 179-187.	3.2	15
111	Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat. Psychopharmacology, 2020, 237, 1147-1160.	3.1	15
112	Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction, 2008, 103, 681-686.	3.3	14
113	Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. Drug and Alcohol Dependence, 2016, 168, 164-169.	3.2	14
114	Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis. Frontiers in Psychiatry, 2018, 9, 283.	2.6	14
115	Medications for substance use disorders (SUD): emerging approaches. Expert Opinion on Emerging Drugs, 2017, 22, 301-315.	2.4	13
116	Opioids, dopamine, stress, and the addictions. Dialogues in Clinical Neuroscience, 2007, 9, 363-378.	3.7	13
117	African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction. Pharmacogenomics, 2016, 17, 995-1003.	1.3	12
118	Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroin. Pharmacogenomics, 2018, 19, 333-341.	1.3	12
119	Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. Neuroscience Letters, 2018, 673, 19-23.	2.1	12
120	Sex and chronic stress differentially alter phosphorylated mu and delta opioid receptor levels in the rat hippocampus following oxycodone conditioned place preference. Neuroscience Letters, 2019, 713, 134514.	2.1	12
121	Review of addiction risk potential associated with adolescent opioid use. Pharmacology Biochemistry and Behavior, 2020, 198, 173022.	2.9	12
122	Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice. Psychopharmacology, 2020, 237, 2405-2418.	3.1	12
123	A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS ONE, 2018, 13, e0199951.	2.5	11
124	Escalation of drug use in persons dually diagnosed with opioid and cocaine dependence: Gender comparison and dimensional predictors. Drug and Alcohol Dependence, 2019, 205, 107657.	3.2	11
125	Chronic immobilization stress primes the hippocampal opioid system for oxycodoneâ€associated learning in female but not male rats. Synapse, 2019, 73, e22088.	1.2	11
126	Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis. Molecular Psychiatry, 2021, 26, 3169-3177.	7.9	11

#	Article	IF	Citations
127	Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handbook of Experimental Pharmacology, 2020, 271, 473-491.	1.8	11
128	Chronic stress differentially alters <scp>mRNA</scp> expression of opioid peptides and receptors in the dorsal hippocampus of female and male rats. Journal of Comparative Neurology, 2021, 529, 2636-2657.	1.6	11
129	Dynorphin A(1-13) Analgesia in Opioid-Treated Patients with Chronic Pain. Clinical Drug Investigation, 1999, 17, 33-42.	2.2	10
130	Persistent increases in rat hypothalamic POMC gene expression following chronic withdrawal from chronic â€œbingeâ€•pattern escalating-dose, but not steady-dose, cocaine. Neuroscience, 2015, 289, 63-70.	2.3	10
131	Endogenous opioid system in addiction and addiction-related behaviors. Current Opinion in Behavioral Sciences, 2017, 13, 196-202.	3.9	10
132	Association of Variants of Arginine Vasopressin and ArginineÂVasopressin Receptor 1A With Severe AcetaminophenÂLiver Injury. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 500-505.	4.5	10
133	Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. New York State Journal of Medicine, 1974, 74, 1970-3.	0.1	10
134	Gender-specific association of functional prodynorphin 68 bp repeats with cannabis exposure in an African American cohort. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1025-1034.	2.2	9
135	Naltrexone and nalmefene attenuate cocaine place preference in male mice. Neuropharmacology, 2018, 140, 174-183.	4.1	9
136	Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. Brain Research, 2019, 1724, 146410.	2.2	9
137	Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. Neuropharmacology, 2020, 167, 107864.	4.1	9
138	Functions of Arginine Vasopressin and Its Receptors: Importance of Human Molecular Genetics Studies in Bidirectional Translational Research. Biological Psychiatry, 2011, 70, 502-503.	1.3	8
139	A 3â€™ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction. PLoS ONE, 2019, 14, e0224399.	2.5	8
140	VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. Pharmacogenomics, 2019, 20, 331-341.	1.3	8
141	Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. Journal of Biomedical Science, 2021, 28, 62.	7.0	8
142	Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist. Handbook of Experimental Pharmacology, 2021, 271, 137-162.	1.8	8
143	Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice. Psychopharmacology, 2018, 235, 2703-2711.	3.1	7
144	Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice. Neuropharmacology, 2020, 176, 108244.	4.1	7

#	Article	IF	Citations
145	OPRD1 SNPs associated with opioid addiction are cis-eQTLs for the phosphatase and actin regulator 4 gene, PHACTR4, a mediator of cytoskeletal dynamics. Translational Psychiatry, 2021, 11, 316.	4.8	7
146	Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. Neuroscience Letters, 2022, 768, 136364.	2.1	7
147	Effects of morphine on prolactin receptors in the rat brain. FEBS Letters, 1994, 338, 207-211.	2.8	6
148	Overview and historical perspective of four papers presented on research related to the endogenous opioid system. Drug and Alcohol Dependence, 2010, 108, 195-199.	3.2	6
149	Regional mRNA expression of GABAergic receptor subunits in brains of C57BL/6J and 129P3/J mice: Strain and heroin effects. Brain Research, 2013, 1523, 49-58.	2.2	6
150	Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. Neuropharmacology, 2020, 181, 108351.	4.1	6
151	Neuroendocrine effects of naltrexone versus nalmefene in humans. Human Psychopharmacology, 2020, 35, e2726.	1.5	6
152	Genetic Vulnerability to Opioid Addiction. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a039735.	6.2	6
153	Immune function in heroin addicts and former heroin addicts in treatment: pre- and post-AIDS epidemic. NIDA Research Monograph, 1990, 96, 192-219.	0.1	6
154	Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. Neuroscience Letters, 2019, 704, 100-105.	2.1	5
155	mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice. Pharmacology Biochemistry and Behavior, 2020, 195, 172954.	2.9	5
156	Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 659-670.	2.2	5
157	Profile of a short-acting Î¹-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice. Journal of Psychopharmacology, 2021, 35, 579-590.	4.0	5
158	Simplified quantitation of urinary benzoylecgonine in cocaine addiction research and for related pharmacotherapeutic trials. Addiction, 1996, 91, 1687-1697.	3.3	4
159	Treating chronic hepatitis C in recovering opiate addicts: yes, we can. Digestive and Liver Disease, 2009, 41, 308-310.	0.9	4
160	Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions. Current Topics in Behavioral Neurosciences, 2016, 39, 175-192.	1.7	4
161	Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?. American Journal on Addictions, 2017, 26, 632-639.	1.4	4
162	Sex and chronic stress alter delta opioid receptor distribution within rat hippocampal CA1 pyramidal cells following behavioral challenges. Neurobiology of Stress, 2020, 13, 100236.	4.0	4

#	Article	IF	Citations
163	Acute effects of ethanol on hepatic uptake and distribution of narcotics in the isolated perfused rabbit liver. Hepatology, 1981, 1, 419-423.	7.3	3
164	Methadone Maintenance Treatment Experience in Macao â€“ Prospective Follow-up for Initial 4.5 Years. Journal of Psychoactive Drugs, 2013, 45, 313-321.	1.7	3
165	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. American Journal of Drug and Alcohol Abuse, 2020, 46, 761-768.	2.1	3
166	Oxycodone injections not paired with conditioned place preference have little effect on the hippocampal opioid system in female and male rats. Synapse, 2021, 75, e22182.	1.2	3
167	Nalmefene, a mu opioid receptor antagonist/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice. Neuropharmacology, 2021, 192, 108590.	4.1	3
168	Kappa Opioids: Problems and Opportunities in Analgesia. ACS Symposium Series, 2013, , 245-256.	0.5	2
169	Kappa Opioid Receptors and Mu Opioid Receptors as Combined Targets for Medication Development for Alcoholism. Biological Psychiatry, 2019, 86, 809-810.	1.3	2
170	Blockade of alcohol excessive and â€œrelapseâ€•drinking in male mice by pharmacological cryptochrome (CRY) activation. Psychopharmacology, 2021, 238, 1099-1109.	3.1	2
171	Acute Delta 9â€tetrahydrocannabinol administration differentially alters the hippocampal opioid system in adult female and male rats. Synapse, 2021, 75, e22218.	1.2	2
172	Age of onset of heaviest use of cannabis or alcohol in persons with severe opioid or cocaine use disorders. Drug and Alcohol Dependence, 2021, 226, 108834.	3.2	2
173	Sex and chronic stress alter the distribution of glutamate receptors within rat hippocampal CA3 pyramidal cells following oxycodone conditioned place preference. Neurobiology of Stress, 2022, 17, 100431.	4.0	2
174	Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold. ACS Chemical Neuroscience, 2022, 13, 1849-1856.	3.5	2
175	Further evidence for the association of GAL, GALR1Âand NPY1RÂvariants with opioid dependence. Pharmacogenomics, 2020, 21, 903-917.	1.3	1
176	The Laboratory of the Biology of Addictive Diseases: Four Women in Neuroscience. Journal of Neuroscience Research, 2021, 99, 29-36.	2.9	1
177	Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder. European Addiction Research, 2021, 27, 198-205.	2.4	1
178	Biological correlates of methadone maintenance pharmacotherapy. Annales De MÃ©decine Interne, 1994, 145 Suppl 3, 9-14.	0.2	1
179	Bruce S. McEwen, Ph.D.. Neuropsychopharmacology, 2020, 45, 1079-1079.	5.4	0